Beam Therapeutics reported widened net losses for Q3 and the nine months ended September 30, 2025. The 9-month Net Loss expanded to \(\\)(324.3M)\( (from \)$(286.4M)\(), driven by sharply declining license/collaboration revenue (\)$25.6M\( vs. \)$33.5M\( YTD) coupled with a significant surge in Research & Development spending. Despite the increased absolute loss, Diluted Net Loss Per Share improved slightly to \)$(3.32)$ due to substantial share count dilution.
Financial Health and Capital Structure: The company maintains strong liquidity, reporting \(\\)1.1$ billion in cash and marketable securi
...